Qu Guangzhi, Perez Edith A
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Semin Oncol. 2002 Jun;29(3 Suppl 11):44-52. doi: 10.1053/sonc.2002.34055.
Gemcitabine, a new cytotoxic nucleoside analog, has demonstrable single-agent antitumor activity in metastatic breast cancer. Recently, nearly 20 phase II clinical trials of gemcitabine alone or as part of combination therapy have confirmed its role in this disease. As a single agent, gemcitabine leads to response rates ranging from 16% to 37% in either first-line and/or refractory settings. Combined with platinum, taxanes, vinorelbine, and anthracyclines as doublets or triplets, response rates in the range of 50% to 80% have been reported in small phase II clinical trials. The relatively mild toxicity profile of gemcitabine makes it an attractive agent to evaluate in combination with targeted drugs such as trastuzumab, tyrosine kinase inhibitors, and angiogenesis inhibitors, among others. In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease.
吉西他滨是一种新型的细胞毒性核苷类似物，在转移性乳腺癌中具有显著的单药抗肿瘤活性。最近，近20项关于吉西他滨单药或作为联合治疗一部分的II期临床试验证实了其在该疾病中的作用。作为单药，吉西他滨在一线和/或难治性治疗中，有效率为16%至37%。在小型II期临床试验中，吉西他滨与铂类、紫杉烷类、长春瑞滨和蒽环类药物联合作为双联或三联方案，有效率在50%至80%之间。吉西他滨相对较轻的毒性特征使其成为一种有吸引力的药物，可用于评估与曲妥珠单抗、酪氨酸激酶抑制剂和血管生成抑制剂等靶向药物联合使用。在本综述中，我们总结了吉西他滨在转移性乳腺癌治疗中的现有数据，并对吉西他滨在该疾病未来临床研究中的应用前景进行了展望。
